Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

CytokineticsCYTK stock surged Tuesday on positive results in a heart disease study where its chief rival, Bristol Myers Squibb'sBMY Camzyos, previously failed. The study, dubbed Acacia-HCM, tested ...

Cytokinetics Inc. CYTK shares are up on Tuesday as the company announced positive topline results from its pivotal Phase 3 ACACIA-HCM trial, which met both dual primary endpoints. The trial evaluated ...

Toho cracks open its vault for the first time, teams with 'Train to Busan' writer Yeon Sang-ho and the Oscar-winning VFX crew ...

The director Ishiro Honda took a break from Godzilla with a villain who could turn himself into a cloud of gas. A new series ...

How do you catch a killer that can literally turn himself into smoke?

Expanding beyond traditional block-based SSD access with new command sets, broader media support, and improved transport ...

The FDA approved another over-the-counter intranasal naloxone product as an emergency treatment for opioid overdoses, the ...

This ETF has been lucrative in recent years, but it comes with an increasingly risky drawback.

Researchers have developed a predictive framework for 2D perovskite design to enable more efficient, stable solar cells.

Aortic stenosis is 1 of the most common heart valve diseases among adults. When symptoms develop, prognosis is poor, and current guidelines recommend prompt aortic valve replacement. Depending of the ...